| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8707222 | Oral Oncology | 2018 | 8 Pages |
Abstract
Despite differences in clinical settings and anti-EGFR inhibitors used for treatment, response prediction by the Cluster3 signature and selected miRNAs was essentially the same. Translation into a useful clinical assay requires validation in a broader setting.
Keywords
ADCCEGFRHNSCCmAbECoGROCGEOAUCFFPEPFsMonoclonal antibodyantibody-dependent cellular cytotoxicityGene expression signaturesprogression-free survivalProgression free survivalSecond line treatmentWorld Health OrganizationHead and neck cancereastern cooperative oncology groupAnti-EGFRconfidence intervalformalin-fixed paraffin-embeddedMiRNAhazard ratioGene Expression OmnibusWHOreceiver operating characteristicEpidermal growth factor receptor
Related Topics
Health Sciences
Medicine and Dentistry
Dentistry, Oral Surgery and Medicine
Authors
Marco Siano, Vittoria Espeli, Nicolas Mach, Paolo Bossi, Lisa Licitra, Michele Ghielmini, Milo Frattini, Silvana Canevari, Loris De Cecco,